NCCN Clinical Practice Guidelines in Oncology: Adolescent and Young Adult Oncology (AYA) Version 2.2027
AYA 定义:确诊年龄 15–39 岁;本指南是跨瘤种支持与照护框架,不是单一肿瘤治疗指南;实体瘤、血液肿瘤方案仍参照对应 NCCN 原发瘤指南(肉瘤、淋巴瘤、白血病、生殖细胞肿瘤、乳腺癌、结直肠癌、宫颈癌、脑肿瘤等)。 核心定位:聚焦 15–39 岁人群特有问题 —— 生育保护、性腺毒性、心理社会、长期迟发效应、依从性、遗传易感性、肿瘤筛查、过渡照护(儿科↔成人肿瘤团队)、临床试验可及性。 适用排除:<15 岁儿童肿瘤(儿科肿瘤指南);≥40 岁成人常规肿瘤人群。
Preface
Adolescent and Young Adult (AYA) patients represent a unique demographic between pediatric and adult oncology. They carry distinct biological, developmental, psychosocial, financial, fertility, and survivorship risks. AYA patients often suffer from diagnostic delay, lower clinical trial enrollment, poor adherence, disruption of education/career/relationships, and unique long‑term treatment sequelae. This 2027.V2 guideline provides a standardized care pathway for AYA patients, complementing site‑specific NCCN disease guidelines.
1. Initial AYA Assessment (At Diagnosis, mandatory)
1.1 基础肿瘤评估
-
Histology, stage, molecular/biomarker testing per primary tumor site guideline
-
Review whether the tumor has pediatric‑type vs adult‑type biology (e.g., sarcoma, ALL, germ cell tumor)
-
MDT discussion: medical oncology, pediatric oncology, surgery, radiation, fertility specialist, genetic counselor, psychology/social work, survivorship nurse navigator
1.2 AYA 专属基线评估模块(本指南核心)
-
Fertility and gonadal function(优先,在性腺毒性治疗前)
-
男性:精液冷冻
-
女性:卵巢组织 cryopreservation, oocyte cryopreservation, ovarian suppression (gonadotropin‑releasing hormone agonist, GnRH-a) as adjuvant protection
-
强调:GnRH‑a cannot replace oocyte/embryo cryopreservation for high‑risk regimens
-
青春期未完成者:性腺毒性风险分层,基线促性腺激素、雌二醇 /testosterone
-
Genetic cancer predisposition
-
早发肿瘤(远低于常规发病年龄)、多发原发癌、家族肿瘤史 → 转诊遗传咨询 + 胚系检测
-
常见:Li‑Fraumeni, Lynch syndrome, hereditary breast/ovarian syndrome, DICER1, RB1, neurofibromatosis
-
Psychosocial & developmental screening
-
Depression, anxiety, PTSD, body image, sexual health, intimate partner violence screening
-
Education, employment, insurance, housing, financial toxicity
-
Transition readiness screening (for patients followed initially in pediatric clinics)
-
Substance use, tobacco, alcohol, cannabis
-
Cognitive function:化疗、颅脑放疗、鞘内治疗相关认知障碍基线记录
-
Sexual health and contraception:强效避孕全程,避免妊娠于放化疗期间
1.3 Clinical trial discussion
Category 2A recommendation: All AYA patients should be offered trial discussion, regardless of disease. NCCN notes AYA historically have the lowest trial accrual compared to children and older adults.
2. Treatment Decision Principles
-
Disease biology first, not only age
-
Some tumors in AYA are best managed with pediatric protocols (e.g., adolescent ALL, Ewing sarcoma, osteosarcoma)
-
Some tumors follow adult protocols (e.g., triple‑negative breast cancer, colorectal cancer, cervical cancer)
-
MDT with both pediatric and adult oncology input is preferred for ambiguous cases
-
Balancing cure vs long‑term toxicity
-
For curable disease: explicitly trade‑off between cure rate, infertility, cardiac dysfunction, second neoplasm risk, neurocognitive injury
-
Avoid overtreatment; avoid automatically applying adult de‑escalation or pediatric intensive regimens without molecular/stage evidence
-
Radiation considerations
-
AYA have higher risk of radiation‑associated second cancers, growth disturbance, hypothyroidism, vascular injury
-
Proton therapy, SBRT, volume reduction techniques should be considered when clinically appropriate to reduce integral dose
-
Surgery:consider functional, cosmetic, fertility impact (pelvic surgery, retroperitoneal surgery)
3. Fertility Preservation & Gonadal Toxicity Surveillance
Before gonadotoxic therapy
-
Urgent referral: ideally within 7–14 days, do not delay curative cancer treatment unnecessarily
-
Male: sperm banking (fastest, lowest barrier)
-
Female:
-
Oocyte cryopreservation: requires ovarian stimulation (2–3 weeks)
-
Embryo cryopreservation: requires partner or donor sperm
-
Ovarian tissue cryopreservation: investigational in many regions, option for those who cannot undergo stimulation
-
GnRH‑agonist cotreatment: adjuvant protective strategy, not standalone
-
Post‑treatment: long‑term monitoring of menstrual function, libido, bone density, hypogonadism
After treatment
-
Hypogonadism management: hormone replacement therapy, except when contraindicated by hormone‑sensitive malignancy
-
Pregnancy surveillance: high‑risk obstetric follow‑up; prior chest radiation needs cardiac/pulmonary assessment before pregnancy
-
Prenatal genetic counseling for survivors with germline predisposition
4. Transition of Care: Pediatric → Adult Oncology
Indications for transition planning: patients followed in pediatric oncology, approaching 18–22 years old
-
Transition plan starts before 18, not at 18
-
Transition checklist: treatment summary, survivorship care plan, cardiology, endocrine, fertility, mental health, primary care linkage
-
Transition readiness assessment: patient’s ability to schedule appointments, manage medications, understand relapse symptoms, communicate independently
-
Shared care period: joint pediatric‑adult clinic visits for overlap
5. Acute Supportive Care Specific to AYA
-
Adherence intervention: AYA have high non‑adherence risk for oral chemotherapy, immunotherapy, endocrine maintenance
-
Digital reminders, care navigators, peer mentorship
-
Chemotherapy-induced nausea/vomiting, pain, fatigue
-
Sexual dysfunction, vaginal atrophy, erectile dysfunction
-
Venous thromboembolism risk: AYA with sarcoma, germ cell tumor, pelvic malignancy, central venous access have elevated VTE risk
-
Immunization: update vaccines before immunosuppressive therapy; live vaccines contraindicated during profound immunosuppression
6. Survivorship & Long‑Term Late Effects Surveillance (core section)
Survivorship care plan (SCP) is mandatory for all AYA after curative intent therapy. Major late‑effect categories:
-
Cardiovascular:anthracycline, chest radiation → cardiomyopathy, coronary artery disease, valvular disease; baseline and periodic echocardiogram, cardiac MRI
-
Endocrine:hypothyroidism, growth hormone deficiency, adrenal insufficiency, premature ovarian insufficiency, testosterone deficiency, metabolic syndrome, diabetes
-
Second primary neoplasms:lifelong cancer surveillance; risk depends on primary tumor, radiation field, chemotherapy agent, germline variant
-
Pulmonary:bleomycin, chest radiation, busulfan → pulmonary fibrosis
-
Musculoskeletal:radiation, sarcoma surgery, steroid → limb length discrepancy, osteoporosis, avascular necrosis
-
Neurocognitive:brain radiation, high‑dose methotrexate, intrathecal therapy → attention, memory, executive function impairment
-
Psychosocial sequelae: chronic fatigue, anxiety, depression, PTSD, social isolation, occupational impairment
Surveillance schedule: stratified by treatment exposures, not by age alone.
7. Recurrent / Metastatic AYA Disease
-
Re‑biopsy / liquid biopsy for molecular profiling when feasible
-
Re‑evaluate fertility options before salvage high‑dose chemotherapy, stem cell transplant
-
Consider palliative care integration early, not only at end‑of‑life
-
Peer support, mental health priority; AYA palliative care needs differ from older adults
8. Genetic Predisposition and Cancer Screening in AYA Survivors
-
If pathogenic germline variant identified: tailored screening for the patient and cascade testing for at‑risk relatives
-
Li‑Fraumeni: intensive whole‑body surveillance protocol
-
Lynch syndrome: colonoscopy, endometrial surveillance
-
Hereditary breast‑ovarian cancer: breast MRI, risk‑reducing surgery discussion when appropriate
-
Important: AYA survivors themselves are at elevated second cancer risk, separate from familial syndrome risk
9. Special Subpopulations within AYA
-
Pregnant AYA cancer patients
-
Multidisciplinary obstetric‑oncology team; balance fetal risk vs maternal cure
-
Chemotherapy generally permissible after first trimester; radiation is usually avoided during gestation
-
Fertility counseling also for pregnancy‑affected survivors
-
Gender‑diverse / transgender AYA
-
Gender‑affirming hormone interaction with cancer therapy, fertility preservation aligned with gender identity goals
-
Inclusive screening and documentation
-
AYA with hematopoietic cell transplant
-
Chronic GVHD, infertility, endocrinopathy, second malignancy, pulmonary complications; specialized long‑term transplant survivorship
10. 2027.V2 Key Updates
-
Formal standardized transition checklist for pediatric-to-adult handoff (new appendix)
-
Expanded guidance on digital health tools and adherence interventions for oral anticancer agents
-
Updated fertility section: refined statement on GnRH‑a; clearer distinction between investigational and established fertility preservation techniques
-
New section on gender‑diverse AYA care, hormone therapy interaction and fertility counseling
-
Strengthened recommendation for germline predisposition testing for AYA solid tumors diagnosed <30 years
-
Revised cardiac surveillance algorithm: cardiac MRI preferred over echo for high anthracycline + chest radiation exposure
-
Explicit note: AYA trial eligibility barriers should be reviewed; exclusion criteria based purely on age (18+) should be challenged where scientifically unnecessary
-
Second primary cancer surveillance harmonized with hereditary syndrome guidelines
11. Guideline Disclaimer
This is a supportive, cross‑cutting framework. Definitive anticancer treatment regimens are governed by the corresponding primary tumor NCCN guidelines (e.g., osteosarcoma, Hodgkin lymphoma, breast cancer, medulloblastoma).
Citation
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Adolescent and Young Adult Oncology Version 2.2027. NCCN.org.